At the recent Heart Failure 2025 conference hosted by the European Society of Cardiology in Belgrade, Dr. Bettina Heidecker, MD, FESC, the Myocarditis Foundation Director of Research and, Head of the Heart Failure and Cardiomyopathy Clinic at the Charité, Universitätsmedizin Berlin, presented groundbreaking insights into the magMa study. This research explores the use of quantum technology to detect myocarditis, an inflammation of the heart muscle. Dr. Heidecker discussed how quantum sensors, known for their high sensitivity, can detect the magnetic fields associated with myocardial inflammation, potentially leading to earlier and more accurate diagnoses.
The magMa study represents a significant advancement in non-invasive cardiac diagnostics. By leveraging quantum sensors to identify subtle magnetic signals from inflamed heart tissue, this technology offers a promising tool for clinicians to detect myocarditis without the need for more invasive procedures. Such innovation could be particularly beneficial for patients experiencing unexplained cardiac symptoms, providing a quicker path to diagnosis and treatment.
Dr. Heidecker’s involvement in this study underscores the Myocarditis Foundation’s commitment to supporting cutting-edge research aimed at improving patient outcomes. Her presentation at Heart Failure 2025 highlights the potential of quantum technology in transforming the landscape of cardiac care.
